<DOC>
	<DOCNO>NCT02703584</DOCNO>
	<brief_summary>All study , demonstrate improve oocyte maturity high pregnancy rate dual trigger retrospective . The investigator therefore aim perform prospective randomize control study normal responder , compare cycle trigger hCG trigger hCG+GnRH agonist .</brief_summary>
	<brief_title>Co Administration GnRH Agonist hCG Final Oocyte Maturation</brief_title>
	<detailed_description>A prospective , randomize , double blind clinical trial . Patients undergo standard clinical hormonal investigation usual IVF . Patients give standard GnRH antagonist IVF protocol prospectively randomize two group : 1. hCG group- trigger final follicular maturation hCG ( Pregnyl 10,000IU ) usual placebo ( normal saline ) - 36 hour prior oocyte aspiration . 2 . The Double trigger group- receive GnRH agonist ( Suprefact 0.5 mg ) hCG ( Pregnyl 10,000IU ) 36 hour prior oocyte aspiration . All patient supplement usual progesterone preparation ( vaginal progesterone suppository ) luteal support . In order increase rate MII 65 % 80 % alpha error 5 % beta error 80 % sample size need 276 total patient group 138 patient group .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Buserelin</mesh_term>
	<criteria>Women one first 3 IVF cycle attempt Women age 1842 . BMI ( body mass index ) 1835 . AMH ( Anti mullerian hormone ) &gt; 1 ng/ml FSHË‚ 20 IU/L . Informed consent . Women low ovarian response Previous enrollment study . AFC &gt; 20 E2 15,000 pmol/l trigger day . hypersensitive Suprefact/Pregny/gonal F/Purigon/Menopur/progesterone , and/or ingredients/components formulation primary ovarian failure pregnancy breastfeed active blood clot undiagnosed uterine genital bleeding endometriosis uncontrolled hypertension ; uncontrolled diabetes abnormal liver kidney function abnormal ECG , e.g . QT prolongation torsades de pointes cancers/tumors , e.g . pituitary adenoma , ovarian cyst , etc . HIV , HBV HCV infection low bone mineral density ( BMD ) increase risk bone fracture , chronic alcohol and/or tobacco use , presume strong family history osteoporosis chronic use drug reduce bone mass anticonvulsant corticosteroid suicidal tendency , history disposition seizure , state confusion , clinically relevant psychiatric disorder , brain lesion Use investigational drug participation investigational study within 30 day prior study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>41 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Double trigger</keyword>
</DOC>